Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register

Study (n=1231) found lower treatment effectiveness in patients on either secukinumab (SK) or ustekinumab for psoriasis in real-world clinical setting than in trial setting, with SK showing superior effectiveness (more achieving PASI ≤2 after 12 months; RR 1.28;95% CI,1.06-1.55).

JAMA Dermatology